--- title: "Contract Research 13Fs: IQVIA, ICON, Charles River, Medpace" type: learn slug: contract-research-13f-iqv-icl-decoder canonical_url: https://13finsight.com/learn/contract-research-13f-iqv-icl-decoder published_at: 2026-05-16T17:55:38.892Z updated_at: 2026-05-16T17:55:42.465Z author: Sarah Mitchell author_title: Education Editor author_url: https://13finsight.com/authors/sarah-mitchell word_count: 512 locale: en source: 13F Insight --- # Contract Research 13Fs: IQVIA, ICON, Charles River, Medpace > IQVIA Holdings, ICON, Charles River Laboratories, Medpace Holdings, plus Fortrea (LabCorp spinoff) and Syneos Health (taken private 2023) anchor US-traded contract research organization (CRO) 13F positioning. Multi-year emerging biotech funding dynamics, oncology clinical trials, plus emerging emerging AI-driven trial design drive distinctive institutional patterns. US-traded contract research organization (CRO) equities form a distinctive pharma services corner of institutional 13F positioning. IQVIA Holdings (IQV), ICON (ICLR, Irish-domiciled US-listed), Charles River Laboratories (CRL, preclinical CRO plus research models), Medpace Holdings (MEDP), Fortrea (FTRE, LabCorp Drug Development spinoff 2023), plus Syneos Health (taken private 2023) anchor the cohort. Multi-year emerging biotech funding dynamics, oncology clinical trials, plus emerging emerging AI-driven trial design drive distinctive institutional positioning.The CRO business modelCROs operate four primary economic engines:Clinical trial outsourcing. Multi-year clinical trial outsourcing drives CRO operator economics. Pharma plus biotech outsource Phase I plus Phase II plus Phase III plus Phase IV clinical trials plus regulatory plus data management plus biostatistics drive operator revenue. Multi-year emerging $80B+ global CRO market growing 8-12% annually.Biotech funding dynamics. Multi-year emerging biotech funding dynamics drives CRO operator economics. Post-2021 biotech IPO funding peak plus 2022-2024 biotech funding decline plus 2025 emerging recovery drive CRO backlog plus book-to-bill dynamics. Multi-year emerging Federal Reserve rate cut plus emerging IPO window reopening drive multi-year emerging biotech funding recovery.Oncology clinical trials. Multi-year emerging oncology clinical trials drives CRO operator economics. Oncology accounting for 40%+ of global clinical trials plus immuno-oncology plus cell therapy plus gene therapy plus antibody-drug conjugates (ADC) plus precision medicine drive oncology trial complexity plus revenue per trial.AI-driven trial design emerging. Multi-year emerging AI-driven trial design emerging drives operator differentiation. IQVIA Decentralized Trial plus IQVIA AI plus Charles River AI plus Medpace AI plus Veeva CTMS plus Reify Health plus Tempus AI drive AI-driven clinical trial design plus patient recruitment plus trial monitoring plus real-world evidence.Major US-traded CRO namesIQVIA Holdings (IQV)Largest global CRO plus Technology & Analytics Solutions plus Research & Development Solutions plus Contract Sales & Medical Solutions plus emerging emerging post-IMS Health-Quintiles merger (2016) plus Ari Bousbib CEO leadership.ICON (ICLR)Irish-domiciled diversified CRO plus post-PRA Health Sciences acquisition (2021 at $12B) plus Steve Cutler CEO leadership.Charles River Laboratories (CRL)Diversified preclinical CRO plus Research Models & Services plus Discovery & Safety Assessment plus Manufacturing Solutions plus James Foster CEO leadership.Medpace Holdings (MEDP)Mid-size full-service CRO plus therapeutic specialty plus August Troendle founder-CEO leadership.Fortrea (FTRE)Post-LabCorp Drug Development spinoff (June 2023) plus Clinical Development plus Enabling Services plus Tom Pike CEO leadership.Syneos Health (taken private)Diversified CRO plus Clinical Solutions plus Commercial Solutions plus taken private by Elliott Investment Management, Patient Square Capital, Veritas Capital 2023 at $7.1B.How institutional managers position around CROsThree patterns appear across smart-money 13Fs:Pattern 1: Quality-compounder concentrationIQV, MEDP-concentrated growth manager positions reflect quality CRO compounding plus emerging IQVIA technology plus MEDP organic growth thesis.Pattern 2: Preclinical positioningCRL-concentrated value-discipline manager positions reflect Charles River preclinical thesis.Pattern 3: Turnaround positioningFTRE-concentrated value-discipline manager positions reflect Fortrea post-spinoff turnaround thesis.How to read CRO 13F positioningThree rules apply:Rule 1: Identify exposureClinical vs preclinical vs commercial have distinct dynamics.Rule 2: Watch book-to-billMulti-year book-to-bill drives operator revenue trajectory.Rule 3: Cross-check biotech fundingMulti-year biotech funding drives CRO demand.What CRO positioning signalsQuality-compounder conviction. Concentrated IQV positions signal quality CRO thesis.Preclinical conviction. Concentrated CRL positions signal preclinical thesis.Turnaround conviction. Concentrated FTRE positions signal Fortrea turnaround thesis.For real-time tracking of CRO 13F activity, see the institutional signals feed. ## FAQ ### What are the major US-traded contract research organizations? Six major US-traded CROs: (1) IQVIA Holdings (IQV) — largest global CRO; (2) ICON (ICLR) — Irish-domiciled post-PRA Health Sciences; (3) Charles River Laboratories (CRL) — preclinical CRO plus research models; (4) Medpace Holdings (MEDP) — mid-size full-service; (5) Fortrea (FTRE) — LabCorp Drug Development spinoff; (6) Syneos Health (taken private by Elliott, Patient Square, Veritas Capital 2023). ### How does clinical trial outsourcing work? Clinical trial outsourcing drives CRO operator economics. Pharma plus biotech outsource Phase I plus Phase II plus Phase III plus Phase IV clinical trials plus regulatory plus data management plus biostatistics drive operator revenue. $80B+ global CRO market growing 8-12% annually. Multi-year pharma plus biotech outsourcing penetration grew from 35% (2010) to 50%+ (2024) plus biotech reliance on CROs drive multi-year tailwind. ### How does biotech funding affect CROs? Biotech funding dynamics drives CRO operator economics. Post-2021 biotech IPO plus funding peak plus 2022-2024 biotech funding decline plus 2025 recovery drive CRO backlog plus book-to-bill dynamics. Multi-year Federal Reserve rate cut plus IPO window reopening drive biotech funding recovery. Multi-year biotech XBI ETF plus biotech IPO calendar plus private biotech funding drive multi-year CRO demand. ### How does oncology clinical trials work? Oncology clinical trials drives CRO operator economics. Oncology accounting for 40%+ of global clinical trials plus immuno-oncology plus cell therapy plus gene therapy plus antibody-drug conjugates (ADC) plus precision medicine drive oncology trial complexity plus revenue per trial. Multi-year oncology Phase 3 trial cost $50-100M+ vs traditional $20-50M plus biomarker plus companion diagnostic drive multi-year complexity. ### How does AI-driven trial design emerging work? AI-driven trial design drives operator differentiation. IQVIA Decentralized Trial plus IQVIA AI plus Charles River AI plus Medpace AI plus Veeva CTMS plus Reify Health plus Tempus AI drive AI-driven clinical trial design plus patient recruitment plus trial monitoring plus real-world evidence. Multi-year emerging AI-driven patient identification plus emerging decentralized clinical trials (DCT) plus emerging digital biomarkers drive multi-year emerging operator positioning. ### What signals CRO cycle inflections? Four signals: (1) book-to-bill plus emerging backlog dynamics; (2) biotech funding plus emerging IPO window dynamics; (3) oncology trial complexity plus emerging revenue per trial; (4) AI-driven trial design plus emerging operator differentiation. Concentrated 13F changes around these signals reveal manager cycle reading. --- Source: 13F Insight — https://13finsight.com/learn/contract-research-13f-iqv-icl-decoder Author: Sarah Mitchell — https://13finsight.com/authors/sarah-mitchell Last updated: 2026-05-16T17:55:42.465Z